3,274 Shares in Novo Nordisk A/S (NYSE:NVO) Acquired by StrongBox Wealth LLC

StrongBox Wealth LLC acquired a new position in shares of Novo Nordisk A/S (NYSE:NVO) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 3,274 shares of the company’s stock, valued at approximately $282,000.

Several other hedge funds and other institutional investors have also bought and sold shares of NVO. Strategic Investment Solutions Inc. IL bought a new position in Novo Nordisk A/S during the 2nd quarter worth approximately $25,000. Daiwa Securities Group Inc. bought a new position in Novo Nordisk A/S in the third quarter valued at approximately $28,000. Capital Performance Advisors LLP bought a new position in Novo Nordisk A/S in the third quarter valued at approximately $42,000. Carolina Wealth Advisors LLC bought a new position in Novo Nordisk A/S in the third quarter valued at approximately $48,000. Finally, M&R Capital Management Inc. lifted its stake in Novo Nordisk A/S by 260.5% in the third quarter. M&R Capital Management Inc. now owns 411 shares of the company’s stock valued at $49,000 after buying an additional 297 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on NVO shares. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. BMO Capital Markets cut their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Finally, UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $140.20.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $82.99 on Thursday. The company has a market cap of $372.42 billion, a price-to-earnings ratio of 26.86, a PEG ratio of 0.92 and a beta of 0.45. Novo Nordisk A/S has a 1-year low of $80.05 and a 1-year high of $148.15. The company’s fifty day simple moving average is $99.26 and its 200 day simple moving average is $118.18. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.